Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of the efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally in Patients with Moderate-to-Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Piclidenoson (Primary) ; Apremilast
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms COMFORT; COMFORT-1
- Sponsors Can-Fite BioPharma
- 14 Mar 2024 According to a Cipher Pharmaceuticals media release, the company continues to collaborate with the Company's partner, Can-Fite Biopharma on its phase III COMFORT study of Piclidenoson used in the treatment of moderate to severe psoriasis
- 29 Jan 2024 According to a Can-Fite BioPharma media release, Positive Data from this trial has been published in the Journal of the European Academy of Dermatology and Venereology (EADV).
- 10 Aug 2023 According to a Cipher Pharmaceuticals media release, In June 2023, Ciphers partner, Canfite Biopharma announced it had received a positive view from the FDA with respect to its registration plan for the pivotal Phase III clinical trial of CF-101 for the treatment of moderate to severe psoriasis